Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes-Reference-Cited by-同舟云学术

Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes

Published:2020-08 Issue:11 Volume:14 Page:943-954
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Fu Hao¹,Nie Shaoping¹^ORCID,Luo Ping¹,Ruan Yang²,Zhang Zichuan³,Miao Huangtai¹,Li Xin³^ORCID,Wen Songnan³,Bai Rong³⁴^ORCID

Affiliation:

1. Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

2. Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

3. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

4. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin TX 78706, USA

Abstract

Aim: This study sought to investigate the relationship between galectin-3 (Gal-3), myocardial fibrosis (MF) and outcomes in acute heart failure. Materials & methods: The single-nucleotide polymorphisms (SNPs) of LGALS3 at rs4644 and rs4652, plasma Gal-3 level, MF and major adverse events (MAEs) were obtained. Results: There was no significant difference in MAEs when categorizing patients by the LGALS3 SNPs at rs4644 and rs4652. The circulating Gal-3 was related to the degree of MF (p < 0.001). Plasma Gal-3 level and MF can predict an increased risk of MAEs (p < 0.001, p = 0.023, respectively). Conclusion: Not the SNPs of LGALS3 but Gal-3 and MF can predict MAEs in acute heart failure at 1 year of follow-up.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2020-0269

Reference30 articles.

1. Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry

2. Donkor A, Cleland J, McDonagh T, Hardman S. National Heart Failure Audit 2016. 11.07. (2016). https://www.nicor.org.uk/wp-content/uploads/2018/11/Heart-Failure-Summary-Report-2016-17.pdf

3. Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

4. Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis

5. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of β1-, β2-Adrenoceptor and LGALS-3 Genes Polymorphisms with the Course of Heart Failure in Patients with Ischemic Heart Disease;Ukrainian Journal of Cardiovascular Surgery;2024-06-27

2. The Impact Of Asphalt Material And Soil Salinity On Crop Growth Of Sunflower;Sumer 1;2023-08-15

3. Galectin-3: A novel prognostic marker for myocardial infarction;Sumer 1;2023-08-15

4. Identification of novel prognostic targets in coronary artery disease and related complications using bioinformatics and next generation sequencing data analysis;2023-02-22

5. The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest;Life;2022-12-08